Pulse Biosciences Files 8-K for Regulation FD Disclosure

TL;DR

**PLSE filed a routine 8-K for Regulation FD disclosure, confirming ongoing SEC compliance.**

AI Summary

Pulse Biosciences, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This filing, under SEC File Number 001-37744, indicates that the company's common stock, with a $0.001 par value per share, is traded on The Nasdaq Stock Market under the symbol PLSE. For investors, this matters because it confirms the company's ongoing compliance with SEC reporting requirements, providing transparency into its operations and financial health, which is crucial for informed investment decisions.

Why It Matters

This filing confirms Pulse Biosciences' adherence to regulatory transparency, ensuring investors have access to timely information about the company's operations and financial standing. It's a routine but important step in maintaining investor confidence.

Risk Assessment

Risk Level: low — This 8-K is a routine compliance filing and does not indicate any new material risks or changes to the company's operations.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating no immediate need for action but reinforcing the importance of staying informed on future, more substantive filings from Pulse Biosciences, Inc.

Key Numbers

• $0.001 — Par value per share (The stated par value of Pulse Biosciences' common stock.)
• 001-37744 — SEC File Number (The unique identifier for Pulse Biosciences' filings with the SEC.)

Key Players & Entities

• Pulse Biosciences, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market (company) — the exchange where Pulse Biosciences' common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock
• January 9, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Na

Filing Documents

• plse20240108_8k.htm (8-K) — 26KB
• ex_613125.htm (EX-99.1) — 11KB
• b01.jpg (GRAPHIC) — 27KB
• b02.jpg (GRAPHIC) — 69KB
• b03.jpg (GRAPHIC) — 31KB
• b04.jpg (GRAPHIC) — 54KB
• b05.jpg (GRAPHIC) — 59KB
• b06.jpg (GRAPHIC) — 55KB
• b07.jpg (GRAPHIC) — 62KB
• b08.jpg (GRAPHIC) — 62KB
• b09.jpg (GRAPHIC) — 55KB
• b10.jpg (GRAPHIC) — 67KB
• b11.jpg (GRAPHIC) — 46KB
• b12.jpg (GRAPHIC) — 66KB
• b13.jpg (GRAPHIC) — 95KB
• b14.jpg (GRAPHIC) — 42KB
• b15.jpg (GRAPHIC) — 54KB
• b16.jpg (GRAPHIC) — 51KB
• b17.jpg (GRAPHIC) — 58KB
• 0001437749-24-000939.txt ( ) — 1479KB
• plse-20240109.xsd (EX-101.SCH) — 3KB
• plse-20240109_def.xml (EX-101.DEF) — 11KB
• plse-20240109_lab.xml (EX-101.LAB) — 15KB
• plse-20240109_pre.xml (EX-101.PRE) — 11KB
• plse20240108_8k_htm.xml (XML) — 2KB

01

Item 7.01 Regulation FD Disclosure.   On January 9, 2024, Pulse Biosciences, Inc., a Delaware corporation (the "Company"), posted an updated investor presentation on its website. The updated investor presentation (the "Investor Deck") discloses recent progress in the Company's ongoing product development programs relating to its proprietary CellFX nsPFA 360 Cardiac Catheter, its CellFX nsPFA Cardiac Clamp, and its CellFX nsPFA Percutaneous Electrode. The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company's website at www.pulsebiosciences.com under "Investors."   Except for the Investor Deck, information contained on, or accessible through, the Company's website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company's filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of January 2024, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.   The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act " ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by th

Financial Statements and Exhibits

Financial Statements and Exhibits.   (d) Exhibits   Exhibit Number Description     99.1 Investor Deck, dated January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     PULSE BIOSCIENCES, INC.               Date: January 9, 2024 By: /s/ Kevin P. Danahy       Kevin P. Danahy       President and Chief Executive Officer (Principal Executive and Principal Financial Officer)      

View Full Filing

View this 8-K filing on SEC EDGAR